Inventor · disambiguated record
Carlos Martinez Alonso
Also filed as: ALONSO CARLOS MARTINEZ
8 granted patents·2 pending applications·214 citations·filing 1994–2010
85Inventor score
Files withPHARMACIA & UPJOHN AB2CONSEJOS SUPERIOR DE INVESTIGA1PHARMACIA AB1PHARMACIA SPAIN S A1PHARMACIA SPAIN SA1
Top patents by PatentIndex Score
10 records- 0189US5776947AUse of quinoline-3-carboxamide compounds for inhibiting the production of tumor necrosis factor (TNF) and/or for the treatment of septic shockPHARMACIA AB·Filed 1994·Granted Jul 7, 1998·110 cites·5 claims
- 0287US6084075AAgonist and antagonist antibodies to the chemokine receptor-2 (CCR2)PHARMACIA & UPJOHN AB·Filed 1997·Granted Jul 4, 2000·93 cites·21 claims
- 0354US8182816B2Methods of treating cancerSANCHEZ-MADRID FRANCISCO·Filed 2010·Granted May 22, 2012·1 cites·5 claims
- 0453US7867475B2Immune regulation based on the depletion of CD69+ cellsUNIV MADRID AUTONOMA·Filed 2004·Granted Jan 11, 2011·1 cites·7 claims
- 0548US5945296AMonoclonal antibodyPHARMACIA & UPJOHN AB·Filed 1997·Granted Aug 31, 1999·6 cites·10 claims
- 0638US2004157332A1Use of beta recombinase in eukaryotic cells, especially for transgenic workFiled 2004·Application pending·0 cites
- 0736US2010227317A1Method for the Molecular Diagnosis of Prostate Cancer and Kit for Implementing SameTHOMSON OKATSU TIMOTHY·Filed 2007·Application pending·0 cites
- 0825US6716594B1Monoclonal antibodyPHARMACIA SPAIN SA·Filed 1999·Granted Apr 6, 2004·1 cites·11 claims
- 0918US6645723B2Method for determining cytokine receptor activation by the use of an antibodyCONSEJOS SUPERIOR DE INVESTIGA·Filed 1998·Granted Nov 11, 2003·0 cites·20 claims
- 1017US6780644B1Use of beta recombinase in eukaryotic cells, especially for transgenic workPHARMACIA SPAIN S A·Filed 1998·Granted Aug 24, 2004·2 cites·41 claims
Join the waitlist — get patent alerts
Get an alert when Carlos Martinez Alonso files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →